$3.82
+0.14 (+3.80%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ZNTL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional
Held by 11 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, PRIMECAP MANAGEMENT CO/CA/, MILLENNIUM MANAGEMENT LLC, +6 more) · FINRA short interest 4.2 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study of Azenosertib (ZN-c3) in Patients With Ovarian CancerNCT04516447Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabineNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine · Biological: Bevacizumab | Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer | 172 | 2028-06-30 | in 680 d | 2026-04-07 |
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionNCT07546500Progression free survival (PFS) per RECIST v1.1 as assessed by InvestigatorRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Investigator's choice of Chemotherapy, Azenosertib | Ovarian Cancer | 420 | 2028-05-31 | in 650 d | 2026-08-12 |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerNCT05128825Objective Response Rate (ORR) defined by RECIST v1.1 [Part 2]Randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: azenosertib | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | 310 | 2026-12-01 | in 103 d | 2026-07-01 |
| A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous CarcinomaNCT04814108Frequency and severity of TEAEsOpen-label · Treatment | Phase 2 | Completed | Drug: Azenosertib | Uterine Serous Carcinoma | 92 | 2025-10-22actual | — | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerNCT05198804To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2DNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: Azenosertib, Niraparib | Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | 117 | 2025-10-15actual | — | 2026-03-18 |
| A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsNCT04158336Dose EscalationRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Azenosertib | Solid Tumor | 274 | 2025-05-06actual | — | 2026-03-18 |
| ZN-c3 in Adult Participants With Metastatic Colorectal CancerNCT05743036Dose Escalation Phase - Incidence of Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to change in therapeutic landscape. | Drug: ZN-c3, Encorafenib, Cetuximab | Metastatic Colorectal Cancer | 44 | 2024-07-16actual | — | 2025-08-08 |
| Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)NCT05682170Observed dose limiting toxicitiesOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: ZN-d5 ZN-c3, ZN-c3 | Acute Myeloid Leukemia (AML) | 40 | 2024-07-02actual | — | 2024-09-19 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisNCT05199337Safety and TolerabilityOpen-label · Treatment | Phase 1/2 | Completed | Drug: ZN-d5 | Amyloidosis, AL Amyloidosis | 18 | 2024-02-14actual | — | 2024-09-19 |
| Phase 1 First in Human Study of ZN-d5 as a Single AgentNCT04500587Observed Dose Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: ZN-d5 | Acute Myeloid Leukemia, Non Hodgkin Lymphoma | 39 | 2023-12-12actual | — | 2024-09-19 |
| A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With OsteosarcomaNCT04833582Incidence of dose-limiting toxicities (DLT) in DLT evaluable subjects and the incidence and severity of adverse events.Open-label · Treatment | Phase 1 | Completed | Drug: Azenosertib, Gemcitabine | Osteosarcoma | 31 | 2023-08-30actual | — | 2026-04-03 |
| A Food Effect Study of ZN-d5 in Healthy Female VolunteersNCT04854174ZN-d5 BioavailabilityOpen-label · Other | Phase 1 | Completed | Drug: ZN-d5 | Healthy Volunteers | 16 | 2021-06-30actual | — | 2024-09-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19